Mattern Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Mattern Capital Management's VRTX Position: Q2 2026 in Review
Mattern Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 9.2% in Q2 2026, buying an estimated $157K and bringing the position to 4,232 shares worth $2.1M. The position accounts for 0.25% of the portfolio, ranked #87.
Mattern Capital Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Mattern Capital Management held 4,232 shares of Vertex Pharmaceuticals worth $2.1M as of Q2 2026.
- Mattern Capital Management bought 355 Vertex Pharmaceuticals shares in Q2 2026, an estimated $157K.
- Vertex Pharmaceuticals made up 0.25% of Mattern Capital Management's portfolio in Q2 2026, its #87 holding.
- Mattern Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Mattern Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.